Transcranial Focused Ultrasound Neuromodulation 2026
Transcranial Focused Ultrasound Neuromodulation 2026
Transcranial focused ultrasound (tFUS) is transitioning from a research tool to a viable therapeutic platform. Patent filings spanning 2011–2026 reveal accelerating clinical translation across psychiatry, stroke rehabilitation, and neuroregeneration.
How tFUS Neuromodulation Works and Why It Matters
Transcranial focused ultrasound neuromodulation uses pulsed acoustic energy delivered through the intact skull to selectively excite or inhibit neural circuits with millimeter-scale spatial precision. At low acoustic intensities (ISPTA < 3 W/cm²), pulsed tFUS produces reversible neuronal excitability changes without structural tissue damage, distinguishing it fundamentally from high-intensity ablative approaches.
Core technical parameters governing neuromodulatory outcomes include acoustic frequency (commonly 220–650 kHz for transcranial applications), pulse repetition frequency (PRF), duty cycle, sonication duration, and spatial peak temporal average intensity (ISPTA). Excitatory neurons are preferentially activated at higher PRFs, enabling neuron-type-specific targeting by parameter tuning — a finding documented in preclinical rodent models.
The field integrates multiple sub-domains: acoustic beamforming and skull aberration correction, MRI-guided targeting and real-time feedback, closed-loop electrophysiology-coupled delivery, blood-brain barrier opening for drug delivery, and wearable or chronic preclinical systems. The distinction between low-intensity focused ultrasound (LIFU) neuromodulation and high-intensity focused ultrasound (HIFU) ablation is a fundamental axis structuring the patent landscape.
In this dataset, 10 distinct patent records were retrieved spanning 2011–2026. The landscape is distributed across academic institutions and small commercial entities, with no dominant large-device-company assignees visible in retrieved records. Stanford University and Mishelevich, David J. each represent the most active filing entities in this dataset by jurisdictional coverage.
Patent Activity by Technology Cluster and Filing Phase
Analysis of 10 retrieved patent records reveals four primary technology clusters and a clear three-phase innovation trajectory from foundational multi-modality architectures (2011–2016) through validation (2017–2022) to clinical translation filings (2023–2026).
Patents by Technology Cluster — tFUS Dataset
LIFU waveform optimization is the largest single cluster in this dataset, represented by 3 patents, followed by MRI-guided targeting and closed-loop systems with 3 and 3 patents respectively, and multi-modality/BBB architectures with 3 patents in retrieved records.
↗ Click bars to exploretFUS Patent Filings by Phase — Retrieved Records
The clinical translation phase (2023–2026) accounts for 5 of 10 retrieved patents in this dataset, compared with 3 in the foundational phase (2011–2016) and 2 in the development phase (2017–2022), reflecting markedly accelerating clinical-application filings.
↗ Click bars to exploreKey Clinical and Research Application Areas for tFUS Neuromodulation
tFUS neuromodulation is being deployed across seven distinct clinical and research domains, from FDA-approved MRgFUS thalamotomy for essential tremor to early-stage neuroregeneration and psychiatric applications emerging in 2024–2026 filings.
Movement Disorders and Essential Tremor
MRgFUS thermal ablation for essential tremor received FDA approval in 2016 and is the most clinically advanced tFUS application. Patent activity on precision targeting and skull aberration correction — including the Zhejiang University Wenzhou Research Institute 2026 CN patent on dual-modality registration — is directly motivated by movement disorder ablation. Multiple literature sources confirm clinical adoption of MRI-guided thalamotomy for Parkinson’s disease.
Thermal AblationPsychiatric Disorders — Major Depressive Disorder
Stanford University filed two overlapping neurostimulation patents (WO 2024, US pending 2026) anchored to major depressive disorder, with claimed parameter regimes for cortical and subcortical LIFU stimulation mimicking TMS therapeutic profiles. Literature confirms early-phase double-blind crossover studies in depression and mild cognitive impairment. LIFU’s reversibility is presented as enabling psychiatric applications unsuitable for irreversible ablative procedures.
LIFU NeuromodulationStroke Rehabilitation — Neurorehabilitation
The 2026 IN patent from Vellore Institute of Technology Chennai describes a fully closed-loop cortico-thalamic phase-locked tFUS system operating at 480–520 kHz, 0.65–0.72 MPa, 1 Hz PRF, with real-time skull temperature monitoring and cavitation emission detection. MRI-guided BOLD fMRI feedback for monitoring functional connectivity changes relevant to rehabilitation is documented in multiple literature sources from 2023. This represents the dataset’s clearest closed-loop stroke rehabilitation device specification.
Closed-Loop DeviceNeurodegeneration — Alzheimer’s and Parkinson’s
The MBInsight Systems 2026 WO patent describes MRI-guided tFUS activation of neural stem cells at intensities ≤10 W/cm² for neuroregeneration in Alzheimer’s disease, Parkinson’s disease, and mild cognitive impairment. Literature from 2023 documents parameter optimization studies in amnestic mild cognitive impairment participants targeting medial temporal lobe memory structures. This extends tFUS from neuromodulation into regenerative neuromedicine.
NeuroregenerationLeading Patent Assignees in tFUS Neuromodulation — Dataset Snapshot
In this dataset, Stanford University holds the most recent and jurisdictionally broad filings (WO 2024, US 2026) targeting major depressive disorder, while Mishelevich, David J. accounts for the largest single-assignee filing count in retrieved records with 3 US patents spanning 2011–2016 covering multi-modality and BBB-opening architectures.
Top Assignees by Filing Count in Retrieved Records (Dataset Snapshot)
↗ Click bars to exploreStanford University (Leland Stanford)
Stanford University holds 2 filings in this dataset (WO 2024 and US pending 2026), both covering the same LIFU neurostimulation system explicitly targeting major depressive disorder by mimicking TMS therapeutic parameter profiles. The WO 2024 filing claims cortical and subcortical parameter regimes, while the 2026 US pending application extends domestic protection. Both filings are pending, representing the most recent academic IP activity in the retrieved dataset.
United StatesMishelevich, David J.
Mishelevich, David J. holds 3 US filings in this dataset spanning 2011–2016, the highest single-assignee count in retrieved records. The 2011 patent established the earliest multi-modality neuromodulation framework combining DBS, TMS, tDCS, focused ultrasound, optical, and vagus nerve stimulation. The 2016 extension added intersecting ultrasound beam designs, BBB permeability control, and spinal cord neuromodulation. All filings are now inactive or expired status.
United StatesForward-Looking Technology Directions in tFUS (2024–2026 Filings)
The most recent filings in this dataset (2024–2026) reveal five forward-looking directions: psychiatric indications, neuroregeneration, individualized efficacy tracking, closed-loop stroke rehabilitation devices, and subject-specific skull modeling with multi-zone dose optimization.
Psychiatric Indications as Primary Clinical Targets
Both Stanford filings (WO 2024, US 2026) are anchored to major depressive disorder, marking a strategic shift from movement disorders — the established MRgFUS market — toward psychiatry. LIFU’s reversibility and non-invasiveness lower the risk threshold relative to ablative procedures. The broader psychiatric indication space (anxiety, PTSD, addiction, OCD) appears underprotected in this dataset, representing IP white space.
Neuroregeneration via Neural Stem Cell Activation
The MBInsight Systems 2026 WO patent represents a novel paradigm: using tFUS at intensities ≤10 W/cm² not merely to modulate existing neural circuits but to activate endogenous neural stem cells, with claimed applications in Alzheimer’s disease, Parkinson’s disease, and mild cognitive impairment. This extends tFUS from neuromodulation into regenerative neuromedicine, an application domain with limited prior patent coverage in this dataset.
Low-Intensity vs High-Intensity Focused Ultrasound: Key Differences
Click any row to explore further.
| Dimension | LIFU (Low-Intensity FUS) | HIFU (High-Intensity FUS) |
|---|---|---|
| Primary Effect | Reversible modulation of neuronal excitability | Irreversible thermal ablation of tissue |
| Intensity Range | Typically ISPTA < 3 W/cm² | High intensities sufficient for tissue coagulation |
| Tissue Safety | No structural tissue damage at operating parameters | Intentional lesioning; irreversible structural change |
| Clinical Applications | Psychiatry (depression), stroke rehabilitation, cognitive enhancement, pain suppression | Essential tremor thalamotomy (FDA-approved 2016), Parkinson’s disease, neuropathic pain |
| MRI Guidance | Used for targeting and BOLD fMRI feedback monitoring | Required for real-time thermal dose monitoring and safety |
| Key Patent Examples | Stanford Univ. WO 2024, Vellore Institute IN 2026, Carnegie Mellon US 2021 | Zhejiang Univ. CN 2026 (dose optimization for ablation targeting) |
| Reversibility | Fully reversible; enabling psychiatric and chronic-use applications | Irreversible; limiting use to conditions where permanent lesion is therapeutic |
| BBB Opening | Exploited with microbubbles for drug/gene delivery (Mishelevich 2016, literature 2019–2021) | Not the primary mechanism; thermal effect dominates |
Frequently Asked Questions: Transcranial Focused Ultrasound Neuromodulation
Based on retrieved records, acoustic frequencies for transcranial applications commonly range from 220 to 650 kHz. The Vellore Institute of Technology 2026 patent specifies a closed-loop stroke rehabilitation system operating at 480–520 kHz.
According to preclinical rodent model findings in the retrieved dataset, excitatory neurons are preferentially activated at higher PRFs while inhibitory neurons respond less selectively. This enables neuron-type-specific targeting by tuning the PRF parameter without changing transducer position.
Based on retrieved literature, MRgFUS thermal ablation (thalamotomy) received FDA approval for essential tremor in 2016. FDA approval for thalamotomy in neuropathic pain is also noted in the retrieved literature.
Stanford University’s WO 2024 and US pending 2026 patents both target major depressive disorder using LIFU parameters designed to mimic TMS therapeutic profiles. Both filings claim priority from a provisional application titled ‘Low Intensity Focused Ultrasound Treatment for Major Depressive Disorder,’ representing the most recent and jurisdictionally broad academic filings in this dataset.
Multiple literature sources and patent records in this dataset identify skull-induced acoustic aberration as the primary barrier to clinical targeting precision. The Zhejiang University Wenzhou Research Institute 2026 CN patent addresses this by introducing subject-specific transcranial spatial transfer functions combining CT and MRI data, with real-time dose safety interlocking and multi-region dose optimization.
Based on retrieved records, LIFU operates at intensities typically below ISPTA 3 W/cm² and produces reversible changes in neuronal excitability without structural tissue damage, enabling psychiatric and rehabilitation applications. HIFU achieves irreversible thermal ablation and is the basis for FDA-approved thalamotomy. The reversibility distinction is explicitly cited in the Stanford patent filings as enabling psychiatric applications unsuitable for irreversible procedures.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.